Tazemetostat
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-TAZEMETOSTAT |
|---|---|
| Type | Drug |
| Aliases | TazverikТаземетостат |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-EPITHELIOID-SARCOMA DIS-FL |
| Sources | SRC-NCCN-BCELL-2025 |
Drug Facts
| Class | EZH2 inhibitor (oral, selective) |
|---|---|
| Mechanism | Selective oral inhibitor of EZH2 (Enhancer of Zeste Homolog 2) — the catalytic subunit of PRC2 (Polycomb Repressive Complex 2). Blocks H3K27 trimethylation, derepressing tumor-suppressor genes. Effective against both EZH2 wild-type (epigenetic dependence) and Y641 gain-of-function mutated FL — superior response in mutated subset. |
| Typical dosing | 800 mg PO twice daily, continuous until progression or unacceptable toxicity |
| Ukraine registered | False |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-04-27 |
Notes
E7438-G000-101 pivotal trial (Morschhauser 2020): r/r FL after ≥2 prior lines — ORR 69% in EZH2-mutated cohort (CR 13%); ORR 35% in EZH2-WT (CR 4%). FDA-approved both EZH2-mut (per companion test) and EZH2-WT FL (after ≥2 prior lines, no satisfactory alternative). Oral, well-tolerated profile vs cytotoxic salvage — preferred for older / frail r/r FL. Major UA access barrier: not registered.
Used By
Regimens
REG-TAZEMETOSTAT-EPITHELIOID-SARCOMA- Tazemetostat monotherapy (advanced epithelioid sarcoma, SMARCB1/INI1-deficient)REG-TAZEMETOSTAT-FL- Tazemetostat 800 mg PO BID continuous — r/r FL (EZH2-mut OR EZH2-WT after ≥2 lines)